Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Capricor Therapeutics in a research ...
Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have received an average rating of “Buy” from the six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback